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PROTEASOME INHIBITORS

Although the distinct catalytic subunits of the different
proteasome isoforms have been suggested to play roles in
adding antigenic diversity to peptides generated from protein degradation, the catalytic subunits responsible for the
CT-L activity (~5 and 1350 are thought to be most physiologically important and have been recognized as the key
targets of bortezomib and carfilzomib.
Due to the crucial roles of proteasomes in rapidly proliferating cells such as cancer cells, the proteasome has been
exploited as a cancer target, resulting in bortezomib (Velcade®), the first-in-class proteasome inhibitor approved by
the FDA in 2003 for the treatment of relapsed multiple
myeloma (MM). In 2012, a second-generation proteasome
inhibitor carfilzomib was approved by the FDA for the
treatment of relapsed multiple myeloma patients who have
received at least two prior therapies, including bortezomib.
The addition of these proteasome inhibitors to chemotherapeutic armaments has dramatically improved the therapeutic
landscape for patients with multiple myeloma (MM).
Despite the remarkable successes of these drugs in the clinic,
intrinsic and acquired drug resistance remains a major
clinical challenge. Additionally, these drugs have failed to
provide clinical benefit to patients with solid cancers, further
adding to the need for next generation proteasome inhibitors.
Proteasome inhibitors are drugs designed to block and/or
inhibit the ability of cancer cells to use certain proteins to
carry out the cell cycle. When they are unable to complete
this process, the result is the death of the cell. Currently, just
a few proteasome inhibitors are available on the market, but
they are in wide use. They are: Velcade® and Kyprolis®.
VELCADE® (bortezomib) is a targeted treatment, meaning it does not kill cells indiscriminately but rather has a
molecular target it seeks out. VELCADE® is FDA approved
to treat multiple myeloma (a type of bone marrow cancer) as
well as patients with mantle cell lymphoma who have failed
first-line therapy.
KYPROLIS® (carfilzomib) is the second generation proteasome inhibitor approved by the FDA in 2012 for the
treatment of patients with relapsed/refractory multiple
myeloma who have received at least two prior therapies
including bortezomib. Phase II clinical trials found that its
response rate is just under 25% with median duration of
response of 7.8 months and overall survival of -16 months.
Compared to VELCADE®, KYPROLIS® is shown to be a
more selective proteasome inhibitor with reduced off target
side effects such as peripheral neuropathy.
In the last decade, the FDA approvals of the proteasome
inhibitors bortezomib and carfilzomib have greatly
improved the therapeutic landscape for patients with multiple myeloma. Indeed, these FDA approvals have validated
the proteasome as an important target in the treatment of
multiple myeloma. Despite these exciting advancements,
there is still much work to be done to provide inhibitors
which overcome intrinsic and acquired drug resistance,
which have clinical utility outside of multiple myeloma, and
which have improved pharmacokinetic properties.
Accordingly, the subject matter of the present disclosure
relates to the development of novel proteasome inhibitors
and that have improved pharmacokinetic properties and
broader and/or unique treatment applications as compared to
compounds known in the art.

RELATED APPLICATIONS
This application claims priority from U.S. Provisional
Application Ser. No. 61/976,220 filed Apr. 7, 2014, the
entire disclosure of which is incorporated herein by this
reference.
GOVERNMENT INTEREST

10

This invention was made with govermnent support under
R01 CA128903 awarded by National Institutes of Health.
The government has certain rights in the invention.
15

TECHNICAL FIELD
The presently-disclosed subject matter relates to novel
non-peptide proteasome inhibitors, their pharmaceutically
acceptable salts, process(es) for their preparation, pharmaceutical compositions containing the novel non-peptide proteasome inhibitors, and methods of treating disease(s) in a
subject, including cancer, via administration of the nonpeptide proteasome inhibitors.

20

25

INTRODUCTION
The proteasome is a key player in one of the most
fundamental processes in eukaryotic cells, the ubiquitindependent protein degradation pathway. The proteasome is
a large multi-subunit protease that degrades the majority of
cellular proteins. The proteasome also controls critical cellular process, such as the cell cycle, via the regulated
degradation of signaling proteins. By perturbing these processes, inhibition of the proteasome leads to apoptosis,
especially in cancer cells. It is for this reason that proteasome inhibitors have become critically important therapies
in the treatment of multiple myeloma.
The barrel-shaped 20S core of the proteasome consists of
four stacked heptameric rings: two outer a-rings and two
inner ~-rings (FIG. lA). While the two outer a-rings serve
mainly structural roles, the two inner ~-rings have three
catalytic subunits in each ring. In marmnalian cells, there
exist two main proteasome subtypes: the constitutive proteasome (CP) and the irmnunoproteasome (IP). These two
proteasome subtypes differ by the incorporation of two
distinct sets of catalytic subunits. The CP contains the
catalytic subunits ~1, ~2, and ~5, which cleave peptide
bonds after acidic (Caspase-Like, C-L), basic (Trypsin-Like,
T-L) and hydrophobic (Chymotrypsin-Like, CT-L) residues,
respectively. (2) The CP is expressed in all eukaryotic cells
and plays key roles in many important intracellular processes, such as cell cycle progression, development, and
inflarmnation. On the other hand, the immunoproteasome is
expressed in irmnune cells and can be induced in other cell
types upon exposure to inflarmnatory cytokines, such as
interferon-y (INF-y) and tumor necrosis factor-alpha (TNFa). (3)
The 20S irmnunoproteasome core is structurally identical
to the constitutive proteasome except for the incorporation
of catalytic subunits ~1i, ~2i, and ~5i instead of ~1, ~2, and
~5, respectively (FIG. lB). The catalytic activities of the
immunoproteasome subunits ~2i and ~5i are relatively similar to that of their constitutive proteasome counterparts,
possessing T-L and CT-L activity, respectively. In contrast,
the replacement of ~1 with ~1i results in a more significant
change in the cleavage specificity from C-L to CT-L.
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The presently-disclosed subject matter meets some or all
of the above-identified needs, as will become evident to
those of ordinary skill in the art after a study of information
provided in this document.
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This Summary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This
Summary is merely exemplary of the numerous and varied
embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an
embodiment can typically exist with or without the
feature(s) mentioned; likewise, those features can be applied
to other embodiments of the presently-disclosed subject
matter, whether listed in this Summary or not. To avoid
excessive repetition, this Summary does not list or suggest
all possible combinations of such features.
The present disclosure includes non-peptide proteasome
inhibitor, including a compound of formula (I), a pharmaceutically acceptable salt, solvate, or physiologically functiona! derivative thereof:
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The presently-disclosed subject matter further includes a
pharmaceutical composition, which includes at least one
compound according to formula (I) and a pharmaceuticallyacceptable carrier.
The presently-disclosed subject matter also includes a
method of inhibiting a proteasome in a cell, which involves
administering or contacting the compound of formula (I) to
the cell. The administrating or contacting the compound to
the cell can lead to apoptosis of the cell. The cell can be, for
example, a cancer cell.
The presently-disclosed subject matter also includes a
method of treating a disease in a subject, which includes
administering an effective amount of a pharmaceutical composition containing the compound of formula (I) to the
subject. The disease can be, for example, a cancer.
BRIEF DESCRIPTION OF THE DRAWINGS

55

60

65

The novel features of the invention are set forth with
particularity in the appended claims. A better understanding
of the features and advantages of the present invention will
be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the
principles of the invention are used, and the accompanying
drawings of which:
FIG. lA illustrates the 26S proteasome, which is composed of a 20S core and 19S regulatory complex. FIG. lB
presents a schematic representation of subunit composition
within a 20S proteasome core. Each ~-ring contains three
catalytic subunits. FIG. lC provides the chemical structure
of two FDA-approved proteasome inhibitors, bortezomib
(Velcade®) and carfilzomib (Kyprolis®).
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FIG. 2A shows the step-wise screening process employed
to identifY non-peptide proteasome inhibitors of the present
disclosure. FIG. 2B provides a synthetic scheme ofG4. FIG.
2C illustrates properties of G4, one of the compounds that
selectively inhibits subunits responsible for the CT-L and
C-L activities (~5, ~5i, ~1 and ~li), but not for the T-L
activity (~2i) Purified 20S immunoproteasome and constitutive proteasome were used. FIG. 2D shows that G4
induces cancer cell death in lung cancer cell lines with IC 50
values of -7 f.LM.
FIG. 3A illustrates structural features of G4 that are
suitable for modification. FIG. 3B provides G4 derivatives,
illustrating modifications relative to FIG. 3A. FIG. 3C
depicts additional G4 derivatives. FIG. 3D illustrates inhibitory activity of selected G4 derivatives toward the CT-L
activity of the proteasome. FIG. 3E provides screening
results of G4 analogs against the CT-L activity of purified
constitutive proteasome. FIG. 3F illustrates the cytotoxicity
of selected compounds in Pane-l cells. FIG. 3G illustrates
the correlation between the inhibitory potency against the
CT-L activity and cytotoxic effects of G4 analogs. FIG. 3H
illustrates inhibitory activity of selected G4 derivatives
against more clinically relevant proteasome catalytic subunit
X.
FIGS. 4A and 4B illustrate the predicted 05 binding mode
of G4-1 and bortezomib generated by Autodock Vina. 39
FIG. SA shows that G4-1 is effective in inhibiting CT-L
and C-L activities of proteasomes in RPMI 8226 cell
extracts. The inhibitory effects ofG4-1 on the CT-L, C-L and
T-L activities were measured by assessing the hydrolysis of
the fluorogenic proteasome substrates Suc-LLVY-AMC,
Z-LLE-AMC and Boc-LRR-AMC, respectively. FIG. SB
demonstrates that as compared to carfilzomib (Cfz) and
bortezomib (Btz), compound G4-1 has excellent metabolic
stability when tested using liver microsomes prepared from
Balb/c mice and BD UltraPooJT" human liver microsomes.
FIG. SC provides a reaction progress curve with 30 min
preincubation of RPMI 8226 cell extracts and G4-1. The
upward curvature demonstrates that the proteasome was
recovering and that the reaction was reversible. FIG. SD
shows that G4-1 effectively induced cell death in multiple
cancer cell lines. FIG. SE includes the potency of G4-1 in
inducing cell death in BxPC-3 cell lines with acquired
resistance to bortezomib or carfilzomib. FIG. SF provides a
comparison of IC 50 values of BxPC-3 sublines resistant to
carfilzomib or bortezomib to its parental cell lines.
FIG. 6 demonstrates that G4-1 inhibits tumor growth in
vivo. Male nude mice bearing LNCaP tumors received
intraperitoneal injections of either G4-1 (5 mg/kg), carfilzomib (5 mg/kg), or vehicle alone (8% DMSO in HP-~
cyclodextrin and sodium citrate) twice a week for 4 weeks
(n=5 mice/group). Results are expressed as mean and standard deviation. FIG. 6A presents tumor growth curves in
animals receiving the respective treatments (*, p<O.OOl,
significantly different from the control group, two-way
ANOVAfollowed by Bonferroni post tests). FIG. 6B & FIG.
6C provide average weights and images of tumors isolated
at the end of the experimental period (*, p<O.OOl, significantly different from the control group, one-way ANOVA
followed by Newman-Keuls post tests). FIG. 6D shows
average body weights of mice receiving the respective
treatments (#, p<O.Ol, significantly different from both G4-1
and control groups, two-way ANOVA followed by Bonferrani post tests). FIG. 6E includes representative images of
mice at the end of the experimental period.

DESCRIPTION OF EXEMPLARY
EMBODIMENTS
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The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom. In case of conflict, the specification of
this document, including definitions, will control.
While the terms used herein are believed to be well
understood by those of ordinary skill in the art, certain
definitions are set forth to facilitate explanation of the
presently-disclosed subject matter. Unless defined otherwise, all technical and scientific terms used herein have the
same meaning as commonly understood by one of ordinary
skill in the art to which the presently-disclosed subject
matter belongs.
Although any methods, devices, and materials similar or
equivalent to those described herein can be used in the
practice or testing of the presently-disclosed subject matter,
representative methods, devices, and materials are now
described.
Unless otherwise indicated, the term "administering" is
inclusive of all means known to those of ordinary skill in the
art for providing a preparation to a subject, including administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration,
intraaural
administration,
intracerebral
administration, intravitreous administration, intracameral
administration, posterior sub-Tenon administration, posterior juxtascleral administration, subretinal administration,
suprachoroidal administration, cell-based administration or
production, rectal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and/or subcutaneous administration. Administration
can be continuous or intermittent. A preparation can be
administered therapeutically; that is, administered to treat an
existing condition of interest. A preparation can be administered prophylactically; that is, administered for prevention
of a condition of interest.
In some embodiments a subject will be administered an
effective amount of at least one compound provided in the
present disclosure. In this respect, the term "effective
amount" refers to an amount that is sufficient to achieve the
desired result or to have an effect on an undesired condition.
For example, a "therapeutically effective amount" refers to
an amount that is sufficient to achieve the desired therapeutic
result or to have an effect on undesired symptoms, but is
generally insufficient to cause adverse side effects. The
specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the
disorder being treated and the severity of the disorder; the
specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of
the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the
specific compound employed and like factors well known in
the medical arts. For example, it is well within the skill of
the art to start doses of a compound at levels lower than
those required to achieve the desired therapeutic effect and
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to gradually increase the dosage until the desired effect is
achieved. If desired, the effective daily dose can be divided
into multiple doses for purposes of administration. Consequently, single dose compositions can contain such amounts
or submultiples thereof to make up the daily dose. The
dosage can be adjusted by the individual physician in the
event of any contraindications. Dosage can vary, and can be
administered in one or more dose administrations daily, for
one or several days. Guidance can be found in the literature
for appropriate dosages for given classes of pharmaceutical
products. In further various aspects, a preparation can be
administered in a "prophylactically effective amount"; that
is, an amount effective for prevention of a disease or
condition.
Additionally, the terms "subject" or "subject in need
thereof' refer to a target of administration, which optionally
displays symptoms related to a particular disease, pathological condition, disorder, or the like. The subject of the herein
disclosed methods can be a vertebrate, such as a mammal, a
fish, a bird, a reptile, or an amphibian. Thus, the subject of
the herein disclosed methods can be a human, non-human
primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea
pig or rodent. The term does not denote a particular age or
sex. Thus, adult and newborn subjects, as well as fetuses,
whether male or female, are intended to be covered. A
patient refers to a subject afflicted with a disease or disorder.
The term "subject" includes human and veterinary subjects.
The term "physiologically functional derivative" means
any pharmaceutically acceptable derivative of a compound
of the present disclosure. For example, an amide or ester of
a compound of formula (I), which upon administration to a
subject, particularly a mmal, is capable of providing,
either directly or indirectly, a compound of the present
disclosure of an active metabolite thereof.
As will be recognized by one of ordinary skill in the art,
the terms "suppression," "suppressing," "suppressor," "inhibition," "inhibiting" or "inhibitor" do not refer to a complete
elimination of angiogenesis in all cases. Rather, the skilled
artisan will understand that the term "suppressing" or
"inhibiting" refers to a reduction or decrease in angiogenesis. Such reduction or decrease can be determined relative
to a control. In some embodiments, the reduction or decrease
relative to a control can be about a 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,
26,27, 28,29,30, 31, 32,33,34, 35,36,37,38, 39,40,41,
42,43, 44,45,46, 47, 48,49, 50, 51, 52, 53, 54, 55, 56, 57,
58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73,
74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% decrease.
In some embodiments the subject in need thereof will be
suffering or will have been diagnosed with one or more
neoplastic or hyperproliferative diseases, disorders, pathologies, or conditions. Examples of such diseases, conditions,
and the like include, but are not limited to, neoplasms
(cancers or tumors) located in the colon, abdomen, bone,
breast, digestive system, esophagus, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovaries, cervix, thymus, thyroid), eye, head and neck,
nervous (central and peripheral), lymphatic system, pelvis,
skin, soft tissue, spleen, thoracic areas, bladder, and urogenital system. Other cancers include follicular lymphomas,
carcinomas with p53 mutations, and hormone-dependent
tumors, including, but not limited to colon cancer, cardiac
tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer,
stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteo-

sarcoma, chondrosarcoma, adenoma, breast cancer, prostate
cancer, Kaposi's sarcoma and ovarian cancer, or metastases
thereof.
A subject may also be in need thereof because they have
acquired diseases or conditions associated with abnormal
and increased cell survival such as, but are not limited to,
progression and/or metastases of malignancies and related
disorders such as leukemia (including acute leukemias (e.g.,
acute lymphocytic leukemia, acute myelocytic leukemia,
including myeloblastic, promyelocytic, myelomonocytic,
monocytic, and erythroleukemia) and chronic leukemias
(e.g., chronic myelocytic (granulocytic) leukemia and
chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not
limited to, sarcomas and carcinomas such as fibrosarcoma,
myxosarcoma, liposarcoma, chondrosarcoma, osteogenic
sarcoma, chordoma, angiosarcoma, endotheliosarcoma,
lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma,
rhabdomyosarcoma, colon carcinoma, pancreatic cancer,
breast cancer, ovarian cancer, prostate cancer, squamous cell
carcinoma, basal cell carcinoma, adenocarcinoma, sweat
gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma,
medullary carcinoma, bronchogenic carcinoma, renal cell
carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor,
cervical cancer, testicular tumor, lung carcinoma, small cell
lung carcinoma, bladder carcinoma, epithelial carcinoma,
glioma, astrocytoma, medulloblastoma, craniopharyngioma,
ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and/or retinoblastoma. The conditions, diseases,
and the like described above, as well as those that will be
apparent to those of ordinary skill in the art, are collectively
referred to as "cancer" herein.
As used herein, the terms "treatment" or "treating" relate
to any treatment of a condition of interest, including but not
limited to prophylactic treatment and therapeutic treatment.
As such, the terms treatment or treating include, but are not
limited to: preventing a condition of interest or the development of a condition of interest; inhibiting the progression
of a condition of interest; arresting or preventing the development of a condition of interest; reducing the severity of a
condition of interest; ameliorating or relieving symptoms
associated with a condition of interest; and causing a regression of the condition of interest or one or more of the
symptoms associated with the condition of interest.
Moreover, the subject matter of the present disclosure
relates to the development of novel proteasome inhibitors
that utilize a non-peptide scaffold. Indeed, the proteasome
inhibitors of the present disclosure avoid the use of peptide
backbone(s) and/or reactive pharmacophores. In some
embodiments, the non-peptide inhibitors of the present
disclosure comprise a substituted pyrazole scaffold, which
provides for relatively potent inhibition of proteasome activity without relying on a peptide-based structure of a reactive
pharmacophore. In some embodiments, the subject matter of
the present disclosure is directed to reversible, non-peptide,
non-covalent inhibitors of the 20S proteasome. The proteasome inhibitors of the present disclosure have improved
pharmacokinetic properties and broader treatment applications than those previously known in the art. In some
embodiments, the non-peptide proteasome inhibitors of the
present disclosure demonstrate activity against multiple
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solid cancer cell lines, including cell lines with acquired
resistance to bortezomib and/or carfilzomib.
The FDA approval of the peptide-based proteasome
inhibitors bortezomib and carfilzomib in 2003 and 2012,
respectively, has validated the proteasome as an important
target in the treatment of multiple myeloma. Additionally,
these inhibitors have demonstrated in vitro as well moderate
in vivo efficacy in preclinical models of solid tumors.
Despite this, clinical trials utilizing these drugs for the
treatment of solid tumors have shown disappointing results.
Although the reasons for these failures remain unclear, one
possibility is that existing proteasome inhibitors such as
bortezomib and carfilzomib lack the pharmacokinetic and
pharmacodynamics properties needed to sufficiently inhibit
proteasomes in solid tumors.
Proteasome inhibitors approved by the FDA are currently
used for the treatment of multiple myeloma and mantle cell
lymphoma. Despite strong indications of activity in preclinical models, proteasome inhibitors in the clinic have failed to
provide clinical benefits for solid cancer patients, presumably due to poor metabolic stability. Research indicates that
this is due to structural and functional properties of these
inhibitors which are shared Pl 'sin clinical development-the
reliance on a peptide backbone coupled with an electrophilic
warhead to mediate covalent binding to the proteasome. It is
believed that it is the structural and functional properties of
known proteasome inhibitors which explain the high failure
rate of those proteasome inhibitors in patients with solid
tumors. (20, 36)
With this in mind, it has been postulated that reversible,
non-peptide proteasome inhibitors could be developed with
improved properties and that these inhibitors could serve
both as novel tools to advance the understanding of the
proteasome and as potential therapeutic options for the
treatment of solid tumors.
In order to identifY novel proteasome inhibitors with
non-peptide scaffolds, the present inventor(s) conducted an
in silica screen of more than 340,000 structures followed by
in vitro assays using purified proteasomes. This screening
effort lead to several novel non-peptide compounds of
interest.
One such compound, a substituted pyrazole derivative,
was used to synthesize a small library of analogues. The
analogue compounds were evaluated for their ability to
inhibit proteasome catalytic activity using specific fluorogenic substrates, and a structure-activity relationship was
developed. In vitro cell viability assays were conducted
against non-small cell lung cancer (NSCLC), pancreatic,
prostate and multiple myeloma cell lines. The in vivo
antitumor activity of the most promising analogue was also
determined using a prostate cancer xenograph model.
Moreover, the substituted pyrazole derivative was found
to have reversible inhibitory activity against the chymotrypsin-like subunits of the 20S constitutive proteasome
and immunoproteasome with single-micromolar IC 50 values. It was equipotent against a series of cancer cell lines
including bortezomib-resistant and carfilozmib-resistant
cancer cell lines, despite varied sensitivity to bortezomib
and carfilzomib. IC 50 values against these cell lines were less
than 10 f.LM. Using the analogue with improved potency and
promising drug-like properties, inhibition of in vivo tumor
growth was also observed.
In some embodiments, the present disclosure provides a
non-peptide proteasome inhibitor of formula (I), a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof:
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Certain compounds of formula (I) may exist in stereoisomeric forms (e.g., they may contain one or more asymmetric carbon atoms, or they may exhibit cis-trans isomerism), and, the individual stereoisomers and mixtures of these
are included within the scope of the present disclosure.
The novel non-peptide proteasome inhibitors of the present disclosure may be used for the treatment of a disease or
condition, such as cancer. In some embodiments, there is
provided a pharmaceutical composition for use in the treatment (including prophylaxis) of one or more conditions or
indications set forth herein, which comprises a compound of
formula I, a pharmaceutically acceptable salt, solvate, or
physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient.
Processes for preparing a pharmaceutically acceptable
salt, solvate and/or a physiologically functional derivative of
the compound(s) of formula (I) are conventional in the art.
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The presently-disclosed subject matter further includes
sodium starch glycollate); or wetting agents (e.g., sodium
Iaury! sulphate). The tablets can be coated by methods
pharmaceutical compositions of the compounds as disclosed
known in the art.
herein, and further includes a pharmaceutically-acceptable
Liquid preparations for oral administration can take the
carrier. In this regard, the term "pharmaceutically acceptable
form
of, for example, solutions, syrups or suspensions, or
carrier" refers to sterile aqueous or non-aqueous solutions,
they can be presented as a dry product for constitution with
dispersions, suspensions or emulsions, as well as sterile
water or other suitable vehicle before use. Such liquid
powders for reconstitution into sterile injectable solutions or
preparations can be prepared by conventional techniques
dispersions just prior to use. Proper fluidity can be mainwith pharmaceutically acceptable additives such as suspendtained, for example, by the use of coating materials such as 10 ing agents (e.g., sorbitol syrup, cellulose derivatives or
lecithin, by the maintenance of the required particle size in
hydrogenated edible fats); emulsifying agents (e.g. lecithin
the case of dispersions and by the use of surfactants. These
or acacia); non-aqueous vehicles (e.g., almond oil, oily
esters, ethyl alcohol or fractionated vegetable oils); and
compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing 15 preservatives (e.g., methyl or propyl-p-hydroxybenzoates or
sorbic acid). The preparations can also contain buffer salts,
agents. Prevention of the action of microorganisms can be
flavoring, coloring and sweetening agents as appropriate.
ensured by the inclusion of various antibacterial and antiPreparations for oral administration can be suitably formufungal agents such as paraben, chlorobutanol, phenol, sorbic
lated to give controlled release of the active compound. For
acid and the like. It can also be desirable to include isotonic
20 buccal administration the compositions can take the form of
agents such as sugars, sodium chloride and the like. Protablets or lozenges formulated in conventional mauner.
longed absorption of the injectable pharmaceutical form can
The compounds can also be formulated as a preparation
be brought about by the inclusion of agents, such as alumifor implantation or injection. Thus, for example, the comnum monostearate and gelatin, which delay absorption.
pounds can be formulated with suitable polymeric or hydroInjectable forms are made by forming microencapsule matri- 25 phobic materials (e.g., as an emulsion in an acceptable oil)
or ion exchange resins, or as sparingly soluble derivatives
ces of the drug in biodegradable polymers such as polylac(e.g., as a sparingly soluble salt).
tide-polyglycolide, poly(orthoesters) and poly(anhydrides).
The compounds can also be formulated in rectal compoDepending upon the ratio of drug to polymer and the nature
sitions (e.g., suppositories or retention enemas containing
of the particular polymer employed, the rate of drug release 30 conventional suppository bases such as cocoa butter or other
can be controlled. Injectable formulations are also prepared
glycerides), creams or lotions, or transdermal patches.
The presently-disclosed subject matter further includes a
by entrapping the drug in liposomes or microemulsions,
kit that can include a compound or pharmaceutical compowhich are compatible with body tissues. The injectable
sition as described herein, packaged together with a device
formulations can be sterilized, for example, by filtration
35 useful for administration of the compound or composition.
through a bacterial-retaining filter or by incorporating sterAs will be recognized by those or ordinary skill in the art,
ilizing agents in the form of sterile solid compositions which
the appropriate administration-aiding device will depend on
can be dissolved or dispersed in sterile water or other sterile
the formulation of the compound or composition that is
injectable media just prior to use. Suitable inert carriers can
selected and/or the desired administration site. For example,
40 if the formulation of the compound or composition is
include sugars such as lactose.
appropriate for injection in a subject, the device could be a
Suitable formulations include aqueous and non-aqueous
syringe. For another example, if the desired administration
sterile injection solutions that can contain antioxidants,
site is cell culture media, the device could be a sterile
buffers, bacteriostats, bactericidal antibiotics and solutes
pipette.
that render the formulation isotonic with the bodily fluids of
Still further, the presently-disclosed subject matter
45
the intended recipient; and aqueous and non-aqueous sterile
includes a method for treating cancer. In some embodiments
suspensions, which can include suspending agents and
the method comprises administering a compound, including
thickening agents.
one of the compounds described herein, to a subject in need
The compositions can take such forms as suspensions,
thereof. In some embodied methods a plurality of comsolutions or emulsions in oily or aqueous vehicles, and can 50 pounds according the present disclosure are administered
contain formulatory agents such as suspending, stabilizing
simultaneously or in a predetermined sequence.
and/or dispersing agents. Alternatively, the active ingredient
There are also provided processes for the preparation of a
can be in powder form for constitution with a suitable
non-peptide proteasome inhibitor according to the present
vehicle, e.g., sterile pyrogen-free water, before use.
disclosure. For example, in some embodiments, the present
The formulations can be presented in unit-dose or multi- 55 disclosure provides processes for the preparation of a comdose containers, for example sealed ampoules and vials, and
pound of formula (I), pharmaceutically acceptable salt,
can be stored in a frozen or freeze-dried condition requiring
solvate, or physiologically functional derivative thereof.
only the addition of sterile liquid carrier immediately prior
Additionally, the present disclosure provides uses of a
to use.
compound of formula (I), a salt, a solvate, or physiological
For oral administration, the compositions can take the 60 derivative thereof in the preparation or manufacture of a
drug and/or medicine, especially a medicine for the treatform of, for example, tablets or capsules prepared by a
conventional technique with pharmaceutically acceptable
ment of cancer in a mammal. In some embodiments, the
cancer is a solid cancer.
excipients such as binding agents (e.g., pregelatinized maize
Proteasome inhibitors according to the present disclosure
starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or 65 were discovered via a virtual screening and medicinal chemcalcium hydrogen phosphate); lubricants (e.g., magnesium
istry approach. The compound of the following formula, for
stearate, talc or silica); disintegrants (e.g., potato starch or
example,
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(also referred to herein as "G4-1"), targets both ~5 and ~5i
and is highly effectively in suppressing tumor growth in a
mouse xenograft model of prostate cancer. Furthermore,
G4-1 is equally effective in killing both parental cells and
model cell lines with acquired resistance to bortezomib or
carfilzomib.
G4-1 was developed by a virtual screen of about 340,000
small molecules against the chymotrypsin-like (CT-L) activity conferring subunit of the proteasome followed by in vitro
screening and subsequent optimization. Unlike carfilzomib
and bortezomib, which contain linear peptide backbones and
are metabolized rapidly, G4-1 shows excellent in vitro
metabolic stability.
Furthermore, G4-1 is highly effective in suppressing
tumor growth with no apparent toxicity in vivo. In addition,
the effectiveness of G4-1 as an anticancer agent is not
reduced by prior resistance to bortezomib or carfilzomib.
Taken together, these results indicate that G4-1 is a metabolically stable proteasome inhibitor with a non-peptide
scaffold that provides a new therapeutic option for multiple
myeloma patients refractory to bortezomib or carfilzomib as
well as for patients with solid cancers.
In some embodiments, the present disclosure provides
non-peptide proteasome inhibitors that suppress tumor
growth.
In some embodiments, the present disclosure provides
methods for treating a subject with solid cancer(s) by
administering to the subject an effective amount of at least
one non-peptide proteasome inhibitor.
In some embodiments, the presently-disclosed subject
matter provides a non-peptide proteasome inhibitor comprising at least one pyrazole. In certain embodiments, the
present disclosure is directed to reversible non-peptide proteasome inhibitors.
In some embodiments, the presently-disclosed subject
matter provides a method of inhibiting a proteasome in a
cell, which involves administering an effective amount of a
compound of formula (I) to the cell. In some embodiments,
administering the compound to the cell leads to apoptosis of
the cell. The cell can be, for example, a cancer cell.
In certain embodiments, the present disclosure provides a
method of treating a disease, wherein the method comprises
administering to a subject at least one non-peptide proteasome inhibitor, wherein the non-peptide proteasome inhibitor comprises at least one pyrazole.
In certain embodiments, the present disclosure provides a
method of treating a disease, wherein the method comprises

20

25

30

35

40

45

50

55

60

administering to a subject an effective amount of a pharmaceutical composition containing at least one compound
according to formula (I).
In some embodiments, the present disclosure is directed
to a pharmaceutical composition comprising at least one
non-peptide proteasome inhibitor, wherein the proteasome
inhibitor includes at least one pyrazole.
In some embodiments, the present disclosure is directed
to a pharmaceutical composition comprising at least one
compound according to formula (I).
In some embodiments, the present disclosure teaches a
method of synthesizing a non-peptide proteasome inhibitor
comprising at least one pyrazole.
In certain embodiments, the subject matter of the present
disclosure includes a compound of formula (I), a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
Further, the present disclosure provides, in certain
embodiments, a method of treating a disease in a subject
comprising the administration of an effective amount of a
pharmaceutical composition containing a non-peptide protease inhibitor, a pharmaceutically acceptable salt, solvate or
physiologically functional derivative thereof and pharmaceutically acceptable excipient to the subject.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so
forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments
±10%, in some embodiments ±5%, in some embodiments
±1 %, in some embodiments ±0.5%, and in some embodiments ±0.1% from the specified amount, as such variations
are appropriate to perform the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples.
The following examples may include compilations of data
that are representative of data gathered at various times
during the course of development and experimentation
related to the present invention.
EXAMPLES
Virtual Screening

65

Structure-based virtual screening was performed following a procedure reported previously by the present inven-
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tors. 23 Briefly, the conformation of proteasomes for virtual
screening was selected from the molecular dynamics trajectory of recently built homology model in complex with
newly discovered highly potent peptide compounds. 24 On
the basis of favorable binding energy and optimal accommodation of the known inhibitors at the active site, the
protein conformation at 341 ps was selected for the final
screening. After docking 345 447 compounds included in
the University of Cincinnati library, 288 compounds for the
experimental validation were selected based on consensus
scoring, force field based energy scoring functions (MMPBSA and MM -GBSA and manual visualization of binding
modes). Out of 288 compounds tested, 19 compounds were
found to be active at 5/4M in a CT-L activity assay using the
IP (more details in the following section). Among these
compounds, G4 was found to potently inhibit the CT-L
activity of the CP and IP. G4-l, an analogue of G-4, was
prepared following a synthetic scheme described in FIG. 2D
and HPLC purification with purity greater than 98%.
Screening Via In Vitro Proteasome Kinetics.
Compounds were dissolved in DMSO and were used at a
concentration of 5 f.LM. The stock concentrations of each
compound were adjusted to make total DMSO percentage
(v/v) less than 1% in the final reaction solution. 20S human
immunoproteasomes (IP) and constitutive proteasomes (CP)
purchased from Boston Biochem were diluted to lx assay
buffer condition (20 mM TrisiC!, pH 8.0, 0.5 mM EDTA,
0.035% SDS). 1, 2 Compounds were pre-incubated with 50
ng/well of IP or CP in a 96-well plate at room temperature
for 90 min. 100 f.LM ofSuc-LLVY-AMC (Sigma) in lx assay
buffer was then added to the wells. Fluorescent signals from
hydrolyzedAMC (Ex: 360 nm, Em: 460 nm) were recorded
once per min up to 90 min. The DMSO treated vehicle
control was used to convert the initial velocities (RFU/min)
to the percent CT-L activity. The data were collected from
three individually performed experiments, and then the
mean, standard deviation values were calculated.
Enzyme Kinetics Assays.
Initially, purified 20S hnman proteasomes (CP and IP,
R&D Systems) were used to assess the in vitro inhibition of
proteasome catalytic activities by G4 and its analogs. In the
96-well format assays involving a 100/4 L total volume, 20S
proteasomes (0.5/4 g/mL) were incubated with G4, its
analogs, or reference compounds (e.g., carfilzomib) in assay
buffer (20 mM Tris-HCI, 0.5 mM EDTA, 0.035% SDS) for
30 min at room temperature. Reactions were initiated by the
addition of individual subunit-selective fluorogenic substrates containing the AMC (7-amino-4-methylcoumarin)
group. The following substrates were used: for /31 activity,
Ac-nLPnLD-AMC (1 00/4M); for /32 and /32i activity, BocLRR-AMC (200/4M); for /35 activity, Ac-WLA-AMC (20/
4M); for /3li activity, Ac-PAL-AMC (100/4M); for /35i
activity, Ac-ANW-AMC (100/4M). The fluorescence of
liberated AMC was measured over a period of 90 min at
room temperature using excitation and emission wavelengths of 360 and 460 nm on a SpectraMax M5 fluorescence plate reader (Molecular Devices).
In separate experiments, cytosolic extracts ofRPMI-8226
or BxPC-3 cells were prepared according to the method of
Kisselev and Goldberg25 and used in place of purified
proteasomes. The fluorescence from liberated AMC of the
subunit-selective probe substrates was measured as
described above.
Jump Dilution Reversibility Assay.
In further investigation of the mode of proteasome inhibition by G4-l, a dilution assay was performed following a
procedure previously reported. 26 Briefly, RPMI 8226 cell

lysates containing 30/4 g of total protein were incubated
with G4-l (10/4M) in 20S proteasome assay buffer for 30
min at room temperature. Lysates treated with G4-l were
subsequently transferred to a semimicrocuvette, and the
baseline proteasome activity was determined by measuring
the hydrolysis rate of Suc-LLVY-AMC. After establishment
of the baseline, lysates treated with G4-l were rapidly mixed
with the 20S proteasome assay buffer, yielding 25-fold
dilution. Following this 25-fold dilution from 10 to 0.4/4M
G4-l, the hydrolysis of Suc-LLVY-AMC was again monitored over approximately 30 min.
Cell Culture.
Human cancer cell lines BxPC-3, H358, H-23, LNCaP,
Pane-l, and RPMI 8226 were obtained from the ATCC
(American Type Culture Collection) and maintained in the
ATCC-recommended media, DMEM or RPMI 1640 supplemented with 10% fetal bovine serum (from GIBCO, CeliGro, and Atlanta Biologicals). BxPC-3 cells with acquired
resistance to bortezomib or carfilzomib were established by
growing them in the presence of stepwise in-creasing concentrations of the respective drug over a period of approximately 6 months. In order to determine the extent of drug
resistance, cytotoxicity assays were performed using
BxPC-3 sublines adapted to 60 nM bortezomib and 200 nM
carfilzomib, respectively.
Measurement of Cytotoxic Effects of G4 and its Analogs.
The cytotoxic effects of G4 and its analogs were determined using CellTiter Glo assay or CellTiter 96 Aqueous
One Solution Cell Proliferation assay (Promega). Adherent
cells (Pane-l, LNCaP, BxPC-3, bortezomib- or carfilzomibresistant BxPC-3 sub lines) growing in log phase were plated
at 7000-10000 cells per well. RPMI 8226 cells growing in
suspension were collected by centrifugation and plated at 10
000 cells per well. Twenty-four hours after plating, media
containing the test compounds were added to each well to
deliver the intended final concentration. After 72 h, the cell
viability was determined using the assay protocol recommended by the manufacturers. The resulting signals were
quantified using a Veritas microplate luminometer or a
SpectraMax M5 microplate spectrophotometer (Molecular
Devices).
Microsomal Stability Assay.
The metabolic stability profiles of G4-l and reference
compounds (carfilzomib and bortezomib) were assessed by
monitoring the disappearance of the test compounds in the
presence of liver microsomes. A typical incubation mixture
(100 sL total volume) for metabolic stability studies contained 1 sM test compounds, 0.5 mg/mL microsomal protein
(pooled Balb/c mouse liver microsomes prepared in-house
or BD UltraPool hnman liver microsomes ), 100 mM TrisHCI buffer (pH 7.4), and NADPH-generating system (5 mM
isocitric acid, 0.2 unit/mL isocitric acid dehydrogenase, 5
mM magnesinm chloride, 1 mM NADP+). After preincubation at 37° C. for 5 min, the reactions were started by
addition of NADP+ and further incubated for another 0, 5,
10, 20 min. For control experiments, NADPH and/or liver
microsomes were omitted from these incubations. The reactions were terminated by adding 100 sL of ice-cold acetonitrile containing phenytoin (1 sM) as internal standard and
keeping on ice for 30 min, followed by centrifugation at 16
100 g for 15 min to obtain the supernatant. Aliquots (5 sL)
were then analyzed for substrate disappearance using liquid
chromatography-tandem mass spectrometry (Agilent 1200
HPLC instrument interfaced with Applied Biosystems Qtrap
3200) equipped with an electrospray ion source.
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In Vivo Efficacy Assay.
Six-week-old male BALB/c athymic nude mice (purchased from Orient Bio Inc., SungNam, Republic of Korea)
were maintained in accordance with the National Institute of
Toxicological Research of the Korea Food and Drug Administration guidelines as well as the regulations for the care and
use of laboratory animals of the animal ethics committee of
the Konyang University. LNCaP cells (2x10 6 cells/50 sL)
were subcutaneously implanted into each animal. After the
xenograft tumors had grown to a size of '-100 mm3 , mice
(n=5/group) were dosed intraperitoneally twice a week for 4
weeks with G4-1 (5 mg/kg), carfilzomib (5 mg/kg), or
vehicle only (8% DMSO in HP-Beta-CD and citrate). Tumor
volumes (calculated using the following formula, (width?x
length/2) and body weights were measured every 4 days
during the experimental period. At the end of the experimental period (at day 30), mice were euthanized by cervical
dislocation and tumors were isolated and weighed.
Results and Discussion
Screening of a Small Molecule Library Against the CT-L
Activity of Proteasomes.
The majority of currently available proteasome inhibitors
including bortezomib and carfilzomib are small peptides
with an electrophilic warhead. 27 These electro-philic warheads such as boronates, epoxyketones, /3-lactones, and
vinyl sulfones directly target the hydroxyl nucleophile of the
N-terminal threonine in the active site, blocking the proteolytic activity of proteasome via covalent modifications. 28
Although the combination of a peptide backbone with an
electrophilic pharmacophore can provide a relatively easy
route to proteasomal inhibition, it may suffer from poor
metabolic stability and side effects. 18 •20 •29 •30 To circumvent
these concerns, increased efforts have been made recently to
generate CT-L activity targeting peptide or non-peptide,
reversible proteasome inhibitors. 31 - 37 However, no further
development has been made to date, mainly because of low
proteasome inhibitory potency or poor in vivo efficacy of
these compounds.
In the current study, the present inventors employed a
stepwise screening strategy to identifY non-peptide proteasome inhibitors lacking reactive warheads with improved
potency and efficacy against proteasomes (FIG. 2A). Given
that the CT-L activity-conferring /35 and /35i subunits share
a high degree of structural homology at the active sites, 38 the
present inventors performed a virtual screening of a library
of 345 447 small molecules (provided by University of
Cincinnati Drug Discovery Center) against the /35i subunit
following a procedure described by us 23 and selected 288
compounds based on their predicted fit into the active site of
/35i.
These selected 288 compounds were then tested for their
ability to inhibit the CT-L activity of proteasomes, and
subsequently G4 was identified as a lead inhibitor (FIG. 2A).
Since only a limited amount of G4 was available from the
library, the present inventors synthesized G4 following the
scheme described in FIG. 2B. Using this synthetic G4
compound, the present inventors found that G4 preferentially inhibits the CT-L activity-conferring /31i and /35//35i
and C-L activity responsible /31 but not /32//32i subunits
which are responsible for T-L activity (FIG. 2C). Consistent
with its ability to inhibit the proteasome activity in vitro, G4
effectively induced cancer cell death in the low micromolar
range (IC50 ,7 sM) (FIG. 2D).
Investigation of the G4 Chemical Space.
To probe structure-activity-relationship of G4 compound,
the present inventors created a library of G4 analogs modified at rings A-D following synthetic procedures similar to

that described in FIG. 2B (FIG. 3A-B; see below for
modified synthetic schemes) and measured their potencies
against the CT-L activity of purified proteasomes. The
enzyme kinetics studies demonstrated that modifications at
rings A and B have significant impacts on inhibitory activity,
G4-1 being one of the most potent inhibitors (FIG. 3D-3F).
In comparison, modifications at the ring D had little impact
on the activity of G4. Interestingly, while most of these G4
derivatives inhibit the CT-L activity of proteasome, some
such as G4-16 and G4-21 activated the CT-L activity of
proteasomes, up to 200% at 10 sM (FIG. 3D). The mechanism by which these compounds enhance the CT-L activity
of proteasome is unclear at this time. While further target
validation study is needed, the initial studies using these
G4-1 derivatives showed an apparent correlation between
the proteasome inhibitory activity and the anticancer effects
of pyrazole-based G4 analogs, indicating that proteasome
inhibition is likely to mediate the cytotoxic effects ofG4 and
G4-1 (FIG. 3G).
With further reference to FIGS. 3C and 3H, Compounds
hydrophobic or water-friendly groups at R1 and/or R2
positions were prepared. Inhibitory activity assay against
more clinically relevant proteasome catalytic subunit X
showed that positively charged groups at R1 and R2 positions are favored for the inhibition of proteasome catalytic
subunit X.
The present inventors next further investigated the structure-activity relationship (SAR) by docking simulation of
G4-1 to the /35 subunit of the proteasome. The docking
studies suggest that the improved activity of G4-1 over G-4
may be attributed to hydrogen bonds created by the introduction of an amide linkage at the ring A (FIG. 4A). Ring B
is predicted to occupy the S3 sub site located at the interface
between /35 and /36 subunits. Ring D of G4-1 is predicted
to occupy the S1 subsite but not as deeply and fully as the
Leu side chain of bortezomib (FIG. 4B). Overall, G4-1 is
predicted to occupy only two subsites, as compared to three
for bortezomib (FIG. 4B), and this predicted difference may
be exploited to further improve inhibitory potency of G4-1.
G4-1 as a Lead Proteasome Inhibitor.
Given its improved inhibitory potency against the CT-L
activity of purified proteasomes and additional optimization
potential (due to the amide linkage at the ring A), as
compared to G4, the present inventors decided to further
characterize G4-1 as a lead non-peptide proteasome inhibitor. It should be mentioned that although compounds G4-40,
G4-41, and G4-42 showed the ability to potently inhibit in
vitro CT-L activity (FIG. 3D), the present inventors found
that G-40, G4-41, and G4-42 were less potent or noncytotoxic in the initial cell viability assays, compared to G4-1
(FIG. 3F), thus justifYing the selection of G4-1 for further in
vitro and in vivo studies. The present inventors first tested
the ability of G4-1 to inhibit the activity of cellular proteasomes present in cell extracts, other than just purified
proteasomes. As shown in FIG. SA, G4-1 was able to
effectively inhibit the proteasomal CT-L and C-L activities
of cell extracts. Similar to G4, G4-1 showed no activity
against the T-L activity of cell extracts.
Given that the majority of currently available proteasome
inhibitors, which contain peptide backbones, are prone to
rapid in vivo inactivation, 31 - 33 •36 the present inventors next
examined whether the pyrazole scaffold-based proteasome
inhibitor G4-1 is metabolically more stable than those
peptide-based drugs. Excitingly, G4-1 demonstrated excellent metabolic stability profiles in mouse and human liver
microsomes, as compared to carfilzomib and bortezomib
(FIG. SB). These results indicate that G4-1 is likely to have
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much improved in vivo stability compared to carfilzomib
and bortezomib, which are known to undergo rapid metabolic inactivation. 18 •21 •40
Next, the present inventors investigated the mode of
proteasome inhibition by G4-1 using a jump dilution reversibility assay previously reported. 26 Preincubation of RPMI
8226 cell extracts with G4-1 for 30 min resulted in a nearly
complete inhibition of proteasomal activity. However, after
25-fold dilution, the reaction rate increased exponentially
with an inhibitor dissociation half-life of approximately 3.2
min (FIG. SC), indicating the reversibility of G4-1/proteasome interaction. As expected, G4-1 showed a good anticancer activity against a variety of cancer cell lines including LNCaP prostate cancer cells (FIG. SD). Interestingly, the
anticancer effect of G4-1 was not negatively impacted by
acquired resistance to bortezomib or carfilzomib in cell line
models (FIG. SE), which was generated by continuous drug
exposure with stepwise increases in concentration (FIG. SF).
In Vivo Anticancer Activity of G4-1.
Lastly, the Present Inventors Investigated the in vivo
anticancer efficacy of G4-1 using a xenograft mouse model.
Given that one of important goals in the area of proteasome
inhibitor therapy is to expand therapeutic benefits to patients
with solid cancers, the present inventors used a solid cancer
xenograft model of human prostate LNCaP cancer cell line
following a procedure the present inventors previously
reported. 6 As shown in FIG. 6A-C, G4-1 effectively suppressed tumor growth in vivo without apparent systemic
toxicity in mice (for images of mice treated with G4-1, see
FIG. 6E). Unlike mice treated with carfilzomib which
resulted in weight loss, mice treated with G4-1 maintained
normal weight gain over the course of treatment (FIG. 6D).
Conclusions
The present inventors have successfully developed a
group of non-peptide, reversible proteasome inhibitors,
including G4-1. This inhibitor utilizes a pyrazole scaffold
and does not rely on an electrophilic warhead to mediate
proteasome inhibition. In addition to its novel scaffold, G4-1
represents an important advance due to its effectiveness in
models of proteasome inhibitor resistance and metabolic
stability. This is notable, as MM patients who are initially
responsive to currently FDA-approved proteasome inhibitors almost inevitably develop resistance to those drugs.
Therefore, G4-1 provides an opportunity for an additional
option for these refractory MM patients. Multiple clinical
trials clearly demonstrated that the clinically approved proteasome inhibitors carfilzomib and bortezomib lack utility in
the treatment of solid tumors due to their rapid metabolism,
irreversible inhibition, sensitivity to resistance, and doselimiting toxic-ities. 18 •20 •22 •41 •42
Synthesis of Compounds
Synthesis of G4.
G4 was synthesized following a procedure described
below and set forth in FIG. 2B.
Compound 2: Hydrazine (0.15 mL, 4.713 mmol) was
added to a solution of 1-(2-Hydroxy-5-methylphenyl)-3phenyl-1, 3-propanedione (1 g, 3.928 mmol) in ethanol (10
mL). The mixture was refluxed with stirring for 1 h. The
mixture was cooled to room temperature. The solvent was
evaporated to dryness. The formed precipitate was taken in
ethyl acetate (30 mL), washed with brine (3x30 mL), and
dried over anhydrous sodium sulfate. The solvent was
evaporated and the solid residue was recrystallized from hot
ethanol. Compound 2 was obtained as yellow solid (955 mg,
97%). 1 H NMR (CDC1 3 , 500 MHz) 6 10.62 (bs, lH), 10.34

(bs, lH), 7.61 (d, 2H, 1=9.5 Hz), 7.49-7.41 (m, 4H), 7.05 (d,
lH, 1=10.0 HZ), 6.96 (d, lH, 1=8.0 Hz), 6.90 (s, lH), 2.34
(s, 3H)
Compound 3: Benzyl 2-bromoacetate (0.14 mL, 0.909
mmol) was added to a solution of Compound 2 (455 mg,
1.818 mmol) in NMP (10 mL). The resulting solution was
heated at about 60-70° C. for 1 hours. The crude product was
purified by column chromatography on silica gel using
hexane-ethyl acetate mixture to afford compound 3 as a
white solid (167 mg, 46%). 1 H NMR (CDC1 3 , 500 MHz) 6
10.38 (s, lH), 7.44-7.28 (m, llH), 7.039 (d, lH, 1=8.0 Hz),
6.93 (d, lH, 1=8.0 Hz), 6.70 (s, lH), 5.18 (s, 2H), 4.92 (s,
2H), 2.31 (s, 3H)
Compound 4: Lithium aluminum hydride (29 mg, 0.764
mmol) was added to a solution of Compound 3 (100 mg,
0.251 mmol) in anhydrous THF (10 mL). The mixture was
stirred at room temperature under nitrogen atmosphere for 2
h. After that period the mixture was carefully poured into ice
water (30 mL) and acidified with 1M HCl at pH 2-3. The
crude product was extracted by ethyl acetate (3x30 mL),
dried over anhydrous sodium sulfate. The solvent was
evaporated and purified by column chromatography on silica
gel using hexane-ethyl acetate mixture to afford compound
4 as a white solid (60mg, 80%).1HNMR (CDC1 3 , 500 MHz)
610.48 (s, lH), 7-53-7.42 (m, 5H), 7.38 (s, lH), 7.039 (d,
lH, 1=8.0 Hz), 6.939 (d, lH, 1 =8.0 Hz), 6.68 (s, lH),
4.32-4.24 (m, 2H), 4.09-4.08 (m, 2H), 2.33 (s, 3H), 1.89 (bs,
lH)
Compound 5: Triethylamine (0.014 mL, 0.102 mmol) was
added to a solution of compound 4 (20 mg, 0.068 mmol) and
4-Toluensulfonyl chloride (14 mg, 0.075 mmol) in dichloromethane (1 mL ). The resulting solution was stirred at rt for
overnight. The reaction mixture was concentrated under
reduced pressure. The crude product was purified by column
chromatography on silica gel using hexane-ethyl acetate
mixture to afford compound 5 as a white solid (13 mg, 43% ).
1
H NMR (CDC1 3 , 500 MHz) 610.02 (s, lH), 7.52-7.45 (m,
7H), 7.31 (s, lH), 7.06-7.03 (m, 3H), 6.89 (d, lH, 1=8.0 Hz),
6.53 (s, lH), 4.43 (t, 2H, 1=5.0 Hz), 4.29 (t, 2H, 1=5.0 Hz),
2.33 (s, 3H), 2.07 (s, 3H)
Compound 6: Triethylamine (0.008 mL, 0.06 mmol) was
added to a solution of compound 5 (9 mg, 0.02 mmol) and
3-(Trifluoromethyl)benzenesulfonyl chloride (0.006 ml,
0.04 mmol) in dichloromethane (1 mL). The resulting solution was stirred at rt for 6 h. The reaction mixture was
concentrated under reduced pressure. The crude product was
purified by column chromatography on silica gel using
hexane-ethyl acetate mixture to afford compound 6 as a
white solid (12 mg, 91%). 1 H NMR (CDC1 3 , 500 MHz)
67.86 (s, lH), 7.737 (d, 2H, 1=8.0 Hz), 7.57 (d, 2H, 1=8.5),
7.49-7.36 (m, 7H) 7.29 (d, lH, 1=8.5 Hz), 7.187.14 (m, 3H),
6.55 (s, lH), 4.42 (t, 2H, 1=5.5 Hz), 4.24 (t, 2H, 1=5.5 Hz),
2.36 (s, 3H), 2.26 (s, 3H)
Compound 7: (R)-(+)-1-Boc-3-aminopyrrolidine (7 mg,
0.0364 mmol) was added to a solution of compound 6 (12
mg, 0.0182 mmol) and potassium carbonate (0.005 mg,
0.0364 mmol) in DMF (0.5 mL). The resulting solution was
stirred at rt for 2 h. The reaction mixture was concentrated
under reduced pressure. The crude product was purified by
column chromatography on silica gel using hexane-ethyl
acetate mixture to afford compound 7 as a white solid (8 mg,
66%). 1 H NMR (CDC1 3 , 500 MHz) 67.92 (s, lH), 7.78-7.76
(m, 2H), 7.57-7.41 (m, 7H), 7.23 (m, lH), 7.13-7.11 (m,
lH), 6.58 (s, lH) 4.17 (m, 2H), 3.89 (m, lH), 3.64-3.22 (m,
6H), 3.03 (m, 2H), 2.37 (s, 3H)
G4: Trifluoroacetic acid (0.5 mL) was added to a solution
of Compound 7 (8 mg, 0.0119 mmol) in dichloromethane (1
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mL). The resulting solution was stirred at rt for 1 h. The
reaction mixture was concentrated under reduced pressure.
The crude product was purified by colunm chromatography
on silica gel using dichloromethane-methanol mixture to
afford G4 as a semi solid (5 mg, 73%). 1 H NMR (CDC1 3 ,
500 MHz) 610.69 (bs, lH), 10.11 (bs, lH), 7.96-7.78 (m,
3H), 7.59-7.35 (m, 7H), 7.13-7.09 (m, 2H), 6.96 (d, lH,
J=8.5 Hz), 6.45 (s, lH), 4.60 (m, 2H), 4.23 (m, lH), 3.85 (m,
2H), 3.61 (m, 4), 2.37 (m, 5H), [a]d"=+l.2 (c=0.14, CHC1 3 )

-continued
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Synthesis of G4-1.
G4-1 was synthesized by the following procedure, which
is further described below.
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Compound 8: Triethylamine (0.02 mL, 0.139 mmol) was
added to a solution of compound 3 (37 mg, 0.0928 mmol)
and 3-(Trifluoromethyl)benzenesulfonyl chloride (0.016
mL, 0.102 mmol) in dichloromethane (1 mL). The resulting
solution was stirred at rt for 1 h. The reaction mixture was
concentrated under reduced pressure. The crude product was
purified by colunm chromatography on silica gel using
hexane-ethyl acetate mixture to afford compound 8 as a
white solid (50 mg, 89%). lH NMR (CDC1 3 , 500 MHz)
67.89 (s, lH), 7.72 d, 2H, 1=7.0 Hz), 7.56 (s, lH), 7.46-7.32
(m, 12H), 7.15 (d, lH, J=8.0 Hz), 6.62 (s, lH), 5.20 (s, 2H),
4.85 (s, 2H), 2.34 (s, 3H)
Compound 9: To a solution of compound 8 (40 mg,
0.0659 mmol) in methanol (2 mL) was added 10% Pd!C (10
mg) and the reaction vessel purged with H 2 gas. The reaction
mixture was stirred under H 2 atmosphere (H 2 balloon) for
0.5 h. Excess H 2 was displaced by air and the catalyst was
removed by filtration through Celite. The filtrate was concentrated under reduced pressure. Compound 9 as a semi
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solid (34 mg, 99%). 1 H NMR (CDC1 3 , 500 MHz) 6 9.22 (bs,
lH), 7.81 (s, lH), 7.71-7.67 (m, 2H), 7.477.33 (m, 8H), 7.16
(d, lH, J=8.0 Hz), 6.48 (s, lH), 4.87 (s, 2H), 2.27 (s, 3H)
Compound 10: N,N-Diisopropylethylamine (0.057 ml,
0.33 mmol) was added to a solution of compound 9 (24 mg,
0.0658 mmol), (R)-( +)-1-Boc-3-aminopyrrolidine (12 mg, 0
0658 mmol), and 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluorobotate (32 mg, 0.099 mmol) in
dichloromethane (2 mL). The resulting solution was stirred
at rt for 2 h. The reaction mixture was concentrated under
reduced pressure. The crude product was purified by column
chromatography on silica gel using hexane-ethyl acetate
mixture to afford compound 10 as a white solid (40 mg,
89%). 1 H NMR (CDC1 3 , 500 MHz) 67.99 (s, lH), 7.88-7.84
(m, 2H), 7.58-7.37 (m, 7H), 7.24 (d, lH, J=8.0 Hz), 6.976.90 (m, lH), 6.72 (s, lH), 6.42 (m, lH), 4.80 (s, 2H),
4.45-4.43 (m, lH), 3.63-3.59 (m, lH), 3.35-3.31 (m, 2H),
3.04 (m, lH), 2.39 (s, 3H), 2.12-2.09 (m, lH), 1.76 (m,
1H)1.37 (s, 9H)
G4-1: Trifluoroacetic acid (0.5 mL) was added to a
solution of compound 10 (20 mg, 0.0292 mmol) in dichloromethane (1 mL ). The resulting solution was stirred at rt for
0.5 h. The reaction mixture was concentrated under reduced
pressure. The crude product was purified by column chromatography on silica gel using dichloromethane-methanol
mixture to afford G4-1 as a semi solid (12 mg, 70%). G4-1
was further purified by HPLC to yield G4-1 with purity
greater than 98.5%. 1 H NMR (CDC1 3 , 500 MHz) 69.22 (bs,
lH), 9.01 (bs, lH), 8.00 (s, lH), 7.88-7.81 (m, 3H), 7.577.39 (m, 7H), 7.13 (d, lH, J=8.0 Hz), 7.11 (d, lH, J=8.0 Hz),
6.55 (s, lH), 4.81 (s, 2H), 4.51 (m, lH), 3.48-3.29 (m, 4H),
2.34-2.27 (m, 4H), 2.05 (m, lH); MS (ESI): M+W,
C 29 H 28 F3 N4 0 4 S, Calcd. 585.1778. found 585.1779.
[aL;s=-11.5 (C=0.23, CHC1 3 )
G4-1 derivatives were synthesized following a procedure
used for the synthesis of G4-1 with exception of using
different starting materials. Representative mnr and mass
data for some G4-1 derivatives (G4-2-G4-13) are provided
below.
G4-2: 1 H NMR (CDC1 3 , 500 MHz) 67.83 (s, lH), 7.74 (d,
2H, 1=7.5 Hz), 7.46-7.15 (m, 9H), 6.51 (s, lH), 4.83 (s, 2H),
2.31 (s, 3H)
G4-3: 1 H NMR (CDC1 3 , 500 MHz) 67.84 (s, lH), 7.757.71 (m, 2), 7.53-7.41 (m, 7H), 7.44 (d, lH, J =8.0 Hz), 7.12
(d, lH, J=8.0 Hz), 6.57 (s, lH), 4.85 (s, 2H), 3.02 (s, 3H),
3.00 (s, 3H), 2.32 (s, 3H)); MS (MALDI-TOF): MW, Calcd.
for C 27 H 25 F3 N 3 0 4 S 544.1. found 544.1.
G4-4: 1 H NMR (CDC1 3 , 500 MHz) 67.96 (s, lH), 7.857.80 (m, 2H), 7.61 (s, lH), 7.54-7.38 (m, 6H), 7.13-7.10 (m,
2H), 6.73 (s, lH), 6.44 (m, lH), 4.78 (s, 2H), 3.08 (d, 2H,
J=8.5 Hz), 2.37 (s, 3H), 0.82 (s, 3H); MS (MALDI-TOF):
MH+, Calcd. 586.2 for C 30 H31 F3 N 3 0 4 S. found 586.2.
G4-5: 1 H NMR (CDC1 3 , 500 MHz) 67.98 (s, lH), 7.877.82 (m, 2H), 7.59-7.46 (m, 5H), 7.99 (d, 2H, J=8.0 Hz),
7.12 (d, lH, 1=7.5 Hz), 7.03 (d, lH, 1=7.5 Hz), 6.70 (s, lH),
6.39 (s, lH), 4.72 (s, 2H), 3.54 (s, 2H), 2.38 (s, 3H), 1.25 (s,
6); MS (MALDI-TOF): MH+, Calcd. for C 29 H 29 F3 N 3 0 5 S
588.2. found 588.2.
G4-6: 1 H NMR (CDC1 3 , 500 MHz) 67.94 (s, lH), 7.847.78 (m, 2H), 7.63 (s, lH), 7.52-7.37 (m, 6H), 7.20-7.14 (m,
2H), 6.61 (m, 2H), 4.73 (s, 2H), 3.97-3.92 (m, lH), 3.753.64 (m, 2H), 3.54-3.50 (m, lH), 3.29-3.26 (m, lH), 2.38 (s,
3H), 1.95-1.78 (m, 3H), 1.53-1.47 (m, lH); MS (MALDITOF): MH+, Calcd. for 600.2. found 600.2.
G4-7: 1 H NMR (CDC1 3 , 500 MHz) 67.97 (s, lH), 7.867.82 (m, 2H), 7.62 (s, lH), 7.57-7.47 (m, 4H), 7.39 (d, 2H,
J=8.0 Hz), 7.14 (d, lH, J=8.0 Hz), 7.08 (d, lH, J=8.0 Hz),

6.71 (s, lH), 6.65 (s, lH), 4.77 (s, 2H), 3.71-3.68 (m, lH),
3.47-3.37 (m, 4H), 3.15-3.13 (m, lH), 2.45-2.43 (m, 2H),
2.38 (s, 3H), 2.372.35 (m, 4H)
G4-8: 1 H NMR (CDC1 3 , 500 MHz) 67.92 (s, lH), 7.867.79 (m, 2H), 7.62 (s, lH), 7.55 (t, lH, 1=7.5 Hz), 7.46-7.41
(m, 5H), 7.13-7.05 (m, 2H), 6.91 (s, lH), 6.61 (s, lH), 4.74
(s, 2), 3.69-3.62 (m, lH), 3.34-3.26 (m, 5H), 2.36-2.31 (m,
5H), 2.04-1.95 (m, 2H), 1.73-1.70 (m, 2H); MS (MALDITOF): MH+, Calcd. for C 32 H32 F3 N4 0 5 S 641.2. found 642.2.
G4-9: 1 H NMR (CDC1 3 , 500 MHz) 67.85-7.83 (m, lH),
7.74-7.67 (m, 2H), 7.54 (s, lH), 7.48-7.23 (m, 12H), 7.127.08 (m, 2H), 6.94-6.89 (m, lH), 6.76 (m, lH), 6.58-6.49
(m, 2H), 5.16-5.14 (m, lH), 4.82 (s, 2H), 3.63-3.53 (m, 2H),
2.98-2.93 (m, 3H), 2.33-2.27 (m, 6H), 2.17-2.12 (m, 2H);
MS (MALDI-TOF): MH+, Calcd. for C42 H38 F3 N 3 0 5 S,
586.2. found 754.2.
G4-10: 1 H NMR (CDC1 3 , 500 MHz) 6 7.87 (s, lH),
7.75-7.71 (m, 2H), 7.61 (s, lH), 7.55-7.34 (m, 7H), 7.15 (d,
lH, J=8.5 Hz), 6.59 (s, lH), 5.33-5.30 (m, lH), 4.84 (s, 2H),
4.66 (d, 2H, 1=7.5 Hz), 2.34 (s, 3H), 1.76 (s, 3H), 1.70 (s,
3H);
MS
(MALDI-TOF):
MK+,
Calcd.
for
C 30 H30 F3 KN 3 0 4 S. 623.2. found 623.2.
G4-11: 1 H NMR (CDC1 3 , 500 MHz) 6 7.86 (s, lH),
7.74-7.70 (m, 2H), 7.53 (s, lH), 7.49-7.32 (m, 7H), 7.16 (d,
lH, J=8.5 Hz), 6.59 (s, lH), 6.32 (s, lH), 5.96 (s, lH), 5.10
(s, 2H), 4.79 (s, 2H), 2.34 (s, 3H), 2.30 (s, 3H)
G4-12: 1 H NMR (CDC1 3 , 500 MHz) 6 8.73 (s, lH), 7.88
(s, lH), 7.76-7.71 (m, 2H), 7.52 (s, lH), 7.49-7.26 (m, 7H),
7.16 (d, lH, J=8.0 Hz), 6.61 (s, lH), 5.33 (s, 2H), 4.81 (s,
2H), 2.47 (s, 3H), 2.35 (s, 3H)
G4-13: 1 H NMR (CDC1 3 , 500 MHz) 6 7.87 (s, lH),
7.76-7.72 (m, 2H), 7.54 (s, lH), 7.49-7.32 (m, 7H), 7.15 (d,
lH, J=8.0 Hz), 6.60 (s, lH), 5.95 (s, lH), 5.21 (s, 2HO, 4.87
(s, 2H), 2.41 (s, 3H), 2.35 (s, 3H)
Throughout this document, various references are mentioned. All such references are incorporated herein by reference, including the references set forth in the following
list:
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13. The compound of claim 1, according to the formula
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15. A pharmaceutical composition, comprising: the compound of claim 1, and a pharmaceutically-acceptable carrier.
16. A method of inhibiting a 26S proteasome in a cell,
comprising administering an effective amount of the compound of claim 1 to the cell.
17. The method of claim 16, wherein the administering
the compound to the cell leads to apoptosis of the cell.
18. The method of claim 16, wherein the cell is a cancer
cell.
19. A method of treating a 26S proteasome-mediated
disease in a subject comprising administering an effective
amount of a pharmaceutical composition containing the
compound of claim 1 to the subject.
20. Themethodofclaim 19, wherein the subject is in need
of treatment for cancer.
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